Microdosing in Silicon Valley: Hype vs. Evidence

Silicon Valley Microdosing

48.9% of active microdosers dosed specifically to go to work

Nearly half of surveyed microdosers weren't exploring consciousness. They were clocking in. Almost a third worked in computer or office roles.

Hutten et al., International Journal of Neuropsychopharmacology, 2019

36.6%

cited performance enhancement as their primary motive for microdosing

191

participants in the leading self-blinding RCT; no significant benefit found over placebo

1 domain

out of four tested survives the 2026 meta-analysis: divergent thinking quality only

Hutten et al., International Journal of Neuropsychopharmacology, 2019

View as image ↗

Nearly half of active microdosers in one survey weren't exploring consciousness. They were going to work.

In a 2019 study of 190 people who currently microdose, 48.9% said they dosed specifically to attend work or study sessions. Almost a third, 29.9%, listed computer or office work as their primary occupation.^[1] That is what microdosing Silicon Valley actually looks like from the inside: not spiritual exploration, but a deliberate performance strategy adopted within a professional working day.

The question this article addresses is whether that strategy is supported by evidence. The cultural story is well documented. The founder of the modern microdosing movement, James Fadiman, began circulating self-experiment protocols through the Bay Area psychedelic community in the early 2010s. By the mid-2010s, microdosing had become a legitimate if informal productivity conversation in tech. By 2018, it had mainstream media coverage and an expanding pool of enthusiastic self-report data. By 2021, it had controlled trials. By 2026, it had a meta-analysis.

This is the full arc of what researchers know, from the first occupational surveys to the most current evidence available. For the broader picture of what microdosing is and how it is practiced, see the complete guide to psilocybin microdosing.

What Microdosing in Silicon Valley Actually Means

Microdosing Silicon Valley-style means taking psilocybin, the active compound in magic mushrooms, at about one-tenth of a recreational dose (0.1g to 0.3g of dried mushroom) on a regular schedule. The practice was structured by James Fadiman in the early 2010s and spread through Bay Area tech culture as a productivity tool.

The dose is small enough that the person does not experience visual effects or perceptual distortion. The goal is subtle enhancement: sharper focus, more creative thinking, reduced anxiety, better mood, all while going about a normal professional workday.

Fadiman, a Stanford-trained psychologist, began collecting self-experiment reports from microdosers and published his initial findings in 2011. His protocol specifies one dose day followed by two rest days, allowing the effects to fade before repeating. This schedule, now called the Fadiman Protocol, became the default starting framework for most tech-adjacent microdosers.^[3] For a full breakdown of how that protocol works, The Fadiman Protocol: The Original Microdosing Schedule covers it in depth.

The appeal to engineers and product managers is legible: a subtle neurochemical tool that improves the quality of thinking without impairing function, fitting the general Silicon Valley framework of optimizing the self as a performance system. Whether that optimization is pharmacologically real is the question that researchers spent the following decade trying to answer.

Who Actually Microdoses for Work: The Occupational Profile

The cultural narrative has data behind it, at least at the level of who is doing this and why.

Hutten and colleagues surveyed 190 currently active microdosers in 2019 and asked detailed questions about their motivations, occupations, and reported experiences.^[1] The occupational breakdown confirmed the tech-adjacent profile. Computer and office workers made up 29.9% of respondents, second only to students at 31.8%. More than a third of participants, 36.6%, cited performance enhancement as their primary reason for microdosing, which ranked higher than any other motivation. And 48.9% reported microdosing specifically to attend a work or study session, not on off days or weekends.

This is not a culture of recreational explorers who happen to hold tech jobs. It is a culture of professionals who have incorporated a controlled substance into a deliberate work-performance strategy.

The side-effect profile from that same survey is worth noting: the most commonly reported adverse effect was perceptual changes on dose days, the opposite of what the practice intends. A subset of respondents found the dosing uncomfortable precisely because the effect was more noticeable than they wanted while trying to work normally.

For a deeper look at what professionals across larger and more recent datasets report about microdosing and work, Microdosing for Work Performance: What Professionals Report pulls together the full evidence picture.

What Microdosers Report: The Survey Evidence

The self-report data from this era is extensive and consistent. Across multiple large surveys, microdosers described similar patterns of benefit.

Anderson and colleagues published an empirical codebook in 2019 that coded qualitative reports from 278 microdosers into categories and counted how often each type of outcome was mentioned.^[2] Improved mood was the most commonly reported benefit, appearing in 26.6% of participant accounts. Improved focus came second at 14.8%. On the challenge side, participants most often described physiological discomfort on dose days and social difficulties from being subtly altered during interactions with others.

Fadiman and Korb's own analysis of self-experiment reports found a similar pattern: most participants described improved focus and elevated mood, and 87% said they intended to continue microdosing after their initial protocol period.^[3]

A 2019 study by Anderson and colleagues added a comparison dimension, measuring 909 microdosers against matched non-microdosers on standardized personality and wellbeing scales.^[4] Microdosers scored higher on openness to experience (Cohen's d=0.32) and on measures of creative thinking. They also scored higher on neuroticism, a finding the researchers flagged without a clear interpretation. The cross-sectional design means this study cannot distinguish between microdosing causing those differences and people with those traits being more likely to microdose in the first place. The comparison tells us that microdosers and non-microdosers differ as groups; it cannot tell us why.

The survey era produced a consistent picture of a population that feels better, thinks more creatively, and focuses more easily when microdosing. What the survey era could not determine was whether psilocybin at sub-threshold doses was responsible for any of that.

The Measurement Problem: Why Surveys Cannot Verify the Claims

Ona and Bouso identified the fundamental problem in a 2020 systematic review of every microdosing study published to that point, 21 studies in total.^[5]

Their finding was stark: the entire evidence base consisted almost entirely of observational studies with high susceptibility to placebo effects. No study had used a design that could distinguish between the pharmacological effects of psilocybin and the effects of believing you were taking something beneficial. There was, they concluded, insufficient evidence to confirm the safety or efficacy of microdosing under any condition.

This is not a critique of the surveys themselves. Observational data is genuine data. But it cannot answer the question "does this work beyond placebo?" for an obvious reason: people who choose to microdose know they are microdosing. They expect to feel better. And when people expect to feel better, they often do, regardless of the active ingredient.

Ona and Bouso called for randomized controlled trials as the field's most urgent methodological need. That call was answered within a year. The results did not confirm what the survey era had suggested.

The Self-Blinding Trial: 191 Participants, No Advantage Over Placebo

Blinding is the central technical challenge of psychedelic research. You cannot give someone psilocybin without them noticing something. Benedek Szigeti's team at Imperial College London solved this problem with a creative citizen-science design: participants prepared their own capsules using their own supply, then had a friend seal and randomize them so that neither the participant nor the researchers knew which capsules contained the active substance on any given day.^[6]

191 participants completed the protocol using LSD or psilocybin at their usual microdosing doses. The results were published in eLife in 2021.

Across every outcome the study tracked (wellbeing, mindfulness, paranoia, and psychological absorption), there was no significant difference between the microdose condition and the placebo condition. The two groups were statistically indistinguishable.

The researchers then looked at what did predict outcomes. Participants in the microdose group had higher expectations of improvement than those in the placebo group, even before the protocol started. And those expectations tracked with the outcomes: higher expected improvement correlated with more reported improvement. Szigeti's team concluded that "the improvements could reflect a placebo response."

This was not a study showing that microdosing has no effect. It was a study showing that, at the doses and schedules most common in Silicon Valley practice, the controlled effects were indistinguishable from what someone experiences when they believe they are receiving a beneficial treatment. That distinction matters. A detailed methodology breakdown of this specific study is available in Is Microdosing Just Placebo? The Self-Blinding Studies.

Why Microdosing Feels Real Even When It May Not Be Pharmacologically Distinct

The reason controlled studies find no effect while thousands of microdosers consistently report improvement is not a mystery. Kaertner and colleagues demonstrated the mechanism directly in a 2021 study of 191 participants.^[7]

Participants rated how much improvement they expected before starting microdosing. Those baseline expectations turned out to be the single strongest predictor of outcomes, with a correlation of r=0.47. More significantly: expectations predicted response more powerfully than the dose taken, the frequency of dosing, or the type of substance used. Expectancy fully statistically mediated the improvements in depression and anxiety that participants reported.

What this means in plain terms: the person who expects microdosing to help their focus and mood will very likely report that their focus and mood improved. The person who approaches it skeptically will report less benefit. The pharmacology of psilocybin adds something to that equation, but in uncontrolled settings it is hard to separate from the expectation layer that sits on top of it.

This is not a reason to dismiss the subjective experience. A genuine expectancy-driven improvement in mood and focus is a real improvement. People feel and perform better. The scientific question is narrower: does psilocybin at microdose levels add anything above and beyond what the expectation itself produces? For a full treatment of how expectancy shapes the microdosing experience, Expectancy Effects in Microdosing: How Belief Shapes Experience goes into the mechanism in depth.

The 2026 Verdict: Creative Ideation Survives, Most Claims Don't

By 2024, enough controlled studies existed to evaluate the productivity claims systematically.

Polito and Liknaitzky reviewed 9 controlled studies and found that none consistently showed benefits beyond placebo for healthy individuals.^[8] Some individual studies showed small positive effects on sustained attention or on divergent thinking in specific conditions. None of those effects replicated reliably across studies. The overall conclusion, carefully worded, was: "it is not yet possible to determine whether microdosing is a placebo." Not "it definitely doesn't work," but "we cannot yet establish that it works beyond placebo on the basis of existing controlled evidence."

Savides and Outhoff's 2024 review identified a core reason for the inconsistency: dosing protocols vary so widely between studies that pooling results is difficult.^[9] One study's "microdose" is another's threshold dose. Different schedules, different substances, different populations, different outcome measures. Until the field standardizes protocols, controlled evidence will remain fragmented across incompatible designs. The review also flagged a cardiac concern for chronic daily users: stimulation of the 5-HT2B receptor, the same pathway implicated in heart valve problems in long-term heavy MDMA users. This concern is considered low-risk for intermittent protocols like the Fadiman schedule, but it remains an open question for anyone dosing daily over extended periods.

Then came the 2026 meta-analysis. Pinhas and colleagues pooled data from all available controlled microdosing studies and measured effects on specific cognitive functions.^[10] This was the first quantitative synthesis of controlled data ever published for microdosing, and it produced a specific, granular verdict:

• Divergent thinking (generating original ideas, the quality of creative ideation): small positive effect favoring microdosing over placebo.
• Convergent thinking (solving problems with a single correct answer, like the Remote Associates Test): no significant effect.
• Attention: no significant effect.
• Executive function (planning, working memory, cognitive flexibility): no significant effect.

The one productivity claim with controlled support is the creativity claim, and only one dimension of creativity. The generative, idea-generating side of creative thought shows a real if modest controlled signal. The analytical, problem-solving side does not. Neither does attention, working memory, nor executive function.

This finding matters for the Silicon Valley framing. The tech worker who microdoses to improve focus during deep coding work, to sharpen analytical problem-solving, to maintain attention across long meetings: the controlled data does not support those goals. The person microdosing to break out of stuck thinking, to generate novel approaches, to improve the quality of brainstorming: there is a controlled signal there, modest in effect size and specific to that one cognitive domain. For how this finding connects to the flow-state question, Microdosing and Flow State: Can It Help You Get in the Zone? examines the neurological mechanisms.

The Honest Current State of the Evidence

The Silicon Valley narrative is not fabricated from nothing. Real people report real benefits, consistently, across thousands of survey respondents spanning a decade of data collection. The Anderson 2019 codebook, the Fadiman self-experiments, the Rootman observational datasets: they all tell the same story of a population that feels meaningfully better when microdosing.

The controlled trial data tells a different and more complicated story. On objective cognitive tests, microdosers and placebo-takers perform similarly. On expectancy measures, microdosers show clear predictive patterns that explain much of the self-reported benefit. And in the first meta-analysis of controlled data, a single cognitive domain, divergent thinking quality, emerges as having genuine pharmacological support while everything else does not.

The most plausible current interpretation is two mechanisms operating simultaneously. First, an expectancy effect that is large, well-documented, and sufficient to account for most of the self-reported improvements in mood, focus, and wellbeing. Second, a genuine pharmacological signal in divergent thinking quality, narrow and modest in effect size but replicable across controlled studies.

The gap between what microdosers feel and what objective measures find is the central unresolved finding in the field. It may mean the cognitive tests are not sensitive enough to detect the real effects. It may mean the benefits are genuine but sub-threshold for standardized measurement. It may mean that most of the effect is expectancy-driven with a narrow pharmacological core. Current data is most consistent with the third interpretation, but the question has not been closed.

What the 2026 evidence does not support is the complete Silicon Valley productivity stack: the idea that a morning microdose reliably improves focus, analytical thinking, attention, mood, and executive function throughout a workday in ways that show up when you actually measure those things. For a claim-by-claim breakdown of which specific productivity claims have controlled support and which don't, Silicon Valley Microdosing: Productivity Claims vs. Controlled Research maps each one against the full study evidence.

The legal and practical dimensions of using a Schedule I substance at work sit alongside the scientific ones. For how the neuroscience of impairment intersects with workplace ethics, including why the cognitive null results from controlled trials actually change the ethical calculus, The Ethics of Microdosing at Work covers the ground that most employment law articles miss.

The Bottom Line

Microdosing Silicon Valley-style developed around a real and consistent user base: surveys show that computer workers and professionals microdose specifically for performance enhancement, and what they report is largely positive. The controlled trial data tells a more complicated story. The most rigorous evidence, including a 2026 meta-analysis, finds no reliable difference from placebo on attention, executive function, convergent thinking, or wellbeing on standardized tests, while finding a small genuine signal for divergent thinking quality. The most plausible current reading is that microdosing produces both a large expectancy-driven effect and a narrow pharmacological signal. The productivity claims that defined the Silicon Valley narrative remain mostly unverified in controlled settings.

Frequently Asked Questions

Does microdosing actually work for productivity?

The answer depends on which component of productivity you mean. A 2026 meta-analysis of controlled studies found no significant effect on attention, executive function, or analytical thinking versus placebo, but did find a small positive effect on divergent thinking quality, specifically the generative, idea-generating component of creative work. For broader productivity measures (sustained focus, working memory, mood on cognitive tests), controlled studies have not found consistent effects beyond what a placebo produces. Survey data from microdosers themselves is consistently positive, but self-reports are heavily shaped by expectancy effects that have been documented directly in the research.

What drugs do tech workers microdose?

Survey data shows tech workers primarily microdose psilocybin, from dried mushrooms, and LSD. A 2019 occupational survey of 190 active microdosers found that computer and office workers made up 29.9% of respondents. Both substances are Schedule I under US federal law, making possession illegal regardless of dose size in any US state, including California.

Is microdosing legal in California?

Psilocybin remains a Schedule I controlled substance under federal law, making it illegal to possess, manufacture, or distribute in California and every other US state. California has not decriminalized psilocybin statewide. Some local jurisdictions, including Santa Cruz and Oakland, deprioritized enforcement, but deprioritization is not legalization and provides no protection against federal prosecution or employer drug policy consequences.

How much psilocybin do you take to microdose?

Most microdosers in research surveys report taking 0.1g to 0.3g of dried mushroom per dose, which corresponds to roughly 1 to 3 milligrams of pure psilocybin, approximately one-tenth of a typical recreational dose. The goal is a dose small enough to produce no perceptual distortion or altered state. Hutten and colleagues (2019) documented that surveyed microdosers most commonly followed a schedule of one dose day followed by two rest days, which follows the structure James Fadiman popularized beginning in the early 2010s.

Who popularized microdosing in Silicon Valley?

James Fadiman, a Stanford-trained psychologist, is most directly credited with structuring the modern microdosing movement. His collection of self-experiment reports from the early 2010s established the dose and schedule framework that tech culture later adopted. Michael Pollan's 2018 book "How to Change Your Mind" brought the practice mainstream visibility beyond psychedelic research circles, though by then microdosing had been circulating in Bay Area tech communities for several years.

Sources & References

1. 1RTHM-01067·Hutten, Nadia R P W et al. (2019). “Motives and Side-Effects of Microdosing With Psychedelics Among Users..” The international journal of neuropsychopharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00541·Anderson, Thomas et al. (2019). “Psychedelic microdosing benefits and challenges: an empirical codebook..” Harm reduction journal.Study breakdown →PubMed →↩
3. 3RTHM-01054·Fadiman, James et al. (2019). “Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration..” Journal of psychoactive drugs.Study breakdown →PubMed →↩
4. 4RTHM-01028·Anderson, Thomas et al. (2019). “Microdosing psychedelics: personality, mental health, and creativity differences in microdosers..” Psychopharmacology.Study breakdown →PubMed →↩
5. 5RTHM-01271·Ona, Genís et al. (2020). “Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review..” Neuroscience and biobehavioral reviews.Study breakdown →PubMed →↩
6. 6RTHM-01441·Szigeti, Balázs et al. (2021). “Self-blinding citizen science to explore psychedelic microdosing..” eLife.Study breakdown →PubMed →↩
7. 7RTHM-01371·Kaertner, L S et al. (2021). “Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing..” Scientific reports.Study breakdown →PubMed →↩
8. 8RTHM-00900·Polito, Vince et al. (2024). “Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
9. 9RTHM-00905·Savides, Isabella A et al. (2024). “Less is more? A review of psilocybin microdosing..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
10. 10RTHM-00961·Pinhas, Netta et al. (2026). “Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis..” Neuroscience and biobehavioral reviews.Study breakdown →PubMed →↩